HCPCS Level II · Drugs administered other than oral method
J1710Injection, hydrocortisone sodium phosphate, up to 50 mg
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1710
J1710 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, hydrocortisone sodium phosphate, up to 50 mg.
It was added to HCPCS effective 01/01/1982, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Hydrocortisone sodium ph inj
- Date added
- 01/01/1982
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1E
Related J17xx codes
- J1700Injection, hydrocortisone acetate, up to 25 mg
- J1720Injection, hydrocortisone sodium succinate, up to 100 mg
- J1726Injection, hydroxyprogesterone caproate, (makena), 10 mg
- J1729Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
- J1730Injection, diazoxide, up to 300 mg
- J1736Injection, meloxicam (delova), 1 mg
- J1737Injection, meloxicam (azurity), 1 mg
- J1738Injection, meloxicam, 1 mg
- J1740Injection, ibandronate sodium, 1 mg
- J1741Injection, ibuprofen, 100 mg
- J1742Injection, ibutilide fumarate, 1 mg
- J1743Injection, idursulfase, 1 mg
Common questions about J1710
Is HCPCS J1710 still valid?
- No. J1710 was terminated on 12/31/2025.
Does Medicare cover J1710?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.